Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Medrx Co.,Ltd.. A complete text table follows the diagram.
The filing reports costs and a small financing-supported revenue base, but no reliable revenue waterfall for the core model.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research and development expenses | 1 | 334M | 62.0% of reported total |
| Selling, general and administrative expenses | 1 | 205M | 38.0% of reported total |
| Other and rounding | 1 | 0 | 0.0% of reported total |
| Pre-revenue biotech operating-cost base | 2 | 538M | Reported six-month total · ¥538M |
| Operating loss | 2 | 609M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.1B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research and development expenses | Pre-revenue biotech operating-cost base | 334M |
| Selling, general and administrative expenses | Pre-revenue biotech operating-cost base | 205M |
| Other and rounding | Pre-revenue biotech operating-cost base | 0 |
| Pre-revenue biotech operating-cost base | Operating costs & expenses | 538M |
| Operating loss | Operating costs & expenses | 609M |